Cebranopadol: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •4 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (3 countries listed)
Risk Assessment
Cebranopadol has not been approved by any regulatory authority. All clinical experience is from controlled trials. NDA submission is planned for 2025 based on Phase 3 acute pain data. Long-term safety in real-world use has not been established.
Despite NOP receptor co-activation reducing certain opioid side effects, cebranopadol retains opioid receptor agonist activity. This means risks of respiratory depression (especially with CNS depressants), physical dependence, and withdrawal symptoms cannot be excluded, particularly with chronic use.
Higher cebranopadol doses (600 mcg) were associated with increased adverse events and treatment discontinuations during the titration phase of chronic pain trials. Careful titration is required for chronic use.
While clinical studies demonstrate lower abuse potential than pure mu-opioid agonists at therapeutic doses, supratherapeutic doses (800 mcg) showed abuse signals comparable to hydromorphone 8 mg. The compound is not free of abuse potential.
⚠️Important Warnings
- •Investigational drug: Cebranopadol is not approved for any indication. Access is limited to clinical trials.
- •Opioid activity: Despite reduced abuse liability, cebranopadol acts at opioid receptors. Risks of respiratory depression, physical dependence, and withdrawal are not eliminated.
- •CNS depression: Do not combine with benzodiazepines, alcohol, or other CNS depressants without medical supervision due to additive sedation and respiratory depression risk.
- •Titration required: For chronic pain use, gradual titration is necessary to minimize adverse events. Higher doses during titration were associated with treatment discontinuation.
- •Long half-life: Terminal half-life of 62-96 hours means effects (both therapeutic and adverse) persist for days. Dose adjustments take approximately 2 weeks to reach new steady state.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | Not FDA-approved. FDA Fast Track designation for chronic low back pain. Two Phase 3 acute pain trials completed with positive results. NDA submission planned for 2025. Currently developed by Tris Pharma. |
| European Union | Investigational | Not EMA-approved. Phase 2 trials were conducted across 11 EU countries. Grunenthal GmbH (original developer) is based in Germany but worldwide rights are now held by Tris Pharma. |
| International | Investigational | Not approved in any jurisdiction. Previously developed by Grunenthal, then licensed to Depomed/Assertio, then Park Therapeutics, and currently Tris Pharma (worldwide rights). |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 10+ community reports
View community protocolsCritical Safety Information#
Cebranopadol (GRT-6005) is an investigational dual NOP/opioid receptor agonist that has not been approved by any regulatory authority. While it demonstrates a differentiated safety profile compared to traditional opioids, it is not devoid of opioid-type risks. All safety information is derived from clinical trials and should be interpreted with appropriate caution.
Investigational Status Risk#
The primary risk is that cebranopadol remains investigational:
- Long-term safety data are limited to 14 weeks (chronic pain Phase 2 trial)
- Rare or delayed adverse events may not yet be identified
- Real-world safety in diverse patient populations has not been established
- No post-marketing surveillance data exist
- Access is currently limited to clinical trial enrollment
Opioid-Related Risks#
Despite the NOP receptor component that reduces certain opioid side effects, cebranopadol retains opioid receptor agonist activity:
Respiratory Depression#
- Preclinical data suggest reduced respiratory depression risk due to NOP co-activation
- No serious respiratory events reported in clinical trials
- Risk may increase with co-administration of CNS depressants (benzodiazepines, alcohol)
- Risk may increase at supratherapeutic doses
Physical Dependence and Withdrawal#
- Chronic opioid receptor activation carries inherent risk of physical dependence
- Withdrawal effects upon discontinuation have not been systematically characterized
- The long half-life may provide some protection against acute withdrawal but could prolong any withdrawal syndrome
Tolerance#
- Long-term tolerance development has not been fully assessed
- 14-week chronic pain data showed sustained efficacy, but longer-term data are needed
Abuse Potential#
Cebranopadol's abuse potential is lower than traditional opioids but not absent:
| Dose | Abuse Assessment | Comparison |
|---|---|---|
| 200 mcg | No difference from placebo | Below clinical concern |
| 400 mcg | No difference from placebo | Below clinical concern |
| 800 mcg | Similar to hydromorphone 8 mg | Moderate signal |
| -- | -- | Lower than hydromorphone 16 mg |
The delayed onset of drug-liking effects (3 hours vs 1.5 hours for hydromorphone) further reduces recreational appeal, as rapid onset is a key driver of subjective reward. If approved, the expected DEA scheduling determination will depend on the totality of abuse potential data.
Regulatory and Legal Status#
Cebranopadol is not approved in any country.
| Jurisdiction | Status | Key Details |
|---|---|---|
| United States (FDA) | Investigational | Fast Track (chronic LBP); Phase 3 positive; NDA planned 2025 |
| European Union (EMA) | Investigational | Phase 2 trials conducted across EU |
| International | Investigational | Worldwide rights held by Tris Pharma |
Risk Mitigation#
For Clinical Investigators#
- Use titration protocols for chronic pain to minimize adverse events
- Monitor for CNS depression, particularly with concomitant sedative use
- Assess patients for history of substance use disorder before enrollment
- Monitor respiratory function, particularly in patients with pulmonary comorbidities
- Counsel patients about the long half-life and delayed dose adjustment effects
For Regulatory Considerations#
- DEA scheduling will be required if approved, based on abuse potential data
- Risk Evaluation and Mitigation Strategy (REMS) may be required
- Post-marketing surveillance for abuse, dependence, and diversion will be essential
Medical Disclaimer#
This information is provided for educational and research purposes only. Cebranopadol is an investigational compound that is not approved for clinical use. No information on this page should be construed as medical advice or a recommendation for treatment. Always consult with a qualified healthcare professional for medical decisions.
Related Reading#
Frequently Asked Questions About Cebranopadol
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.